FDA taps biotech industry veteran as RFK Jr.'s top drug regulator
Tidmarsh, an adjunct professor of pediatrics and neonatology at Stanford University's School of Medicine, Fpauswill lead one of the biggest and most crucial divisions of the FDA, which reviews the vast majority of new drug applications.
The Center for Drug Evaluation and Research, or CDER, regulates over-the-counter and prescription treatments, including biologic therapies and generics. The acting head of CDER, Jacqueline Corrigan-Curay, announced in June she was retiring.
Tidmarsh will step in as the FDA and its regulatory process face massive upheaval under Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy has pursued deep staff cuts across HHS and, in some cases, brought in new employees who either lack relevant scientific and medical experience or share his skepticism of vaccines.
But Tidmarsh's extensive background in the industry and involvement in the development of seven now-approved drugs is likely a sigh of relief for the pharmaceutical industry. His previous comments signal that he could take a more hardline approach to regulating drugs.
In an opinion piece in April, Tidmarsh slammed regulatory decisions made by a key official pushed out of the FDA under Kennedy, Peter Marks. That includes supporting the accelerated approval of Biogen's ill-fated Alzheimer's drug, Aduhelm, and overruling FDA staff to expand approval of Sarepta Therapeutics' Duchenne muscular dystrophy treatment Elevidys.
Last week, the FDA asked Sarepta Therapeutics to halt all shipments of Elevidys after three patients died from liver failure after taking it or a similar treatment. The company later said it would not stop shipments to treat patients with the condition who can still walk, saying data show "no new or changed safety signals" within that group.
Tidmarsh will likely have a say on that controversial accelerated approval process and the FDA's approach to prescription drug advertising. He served as CEO of La Jolla Pharmaceuticals and Horizon Pharma, the latter of which he founded before Amgen bought it for $28 billion. Tidmarsh also founded Threshold Pharmaceutical, and held senior positions at other biotech companies.
"Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development—from bench to bedside," said FDA Commissioner Dr. Marty Makary, in a statement. "His appointment to lead CDER brings exceptional scientific, regulatory, and operational expertise to the agency."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
an hour ago
- Time Business News
Artificial Intelligence Transforming Healthcare and Improving Lives
Artificial intelligence (AI) has emerged as a groundbreaking force reshaping the healthcare landscape. Its rapid advancement over the past decade has led to improved diagnostics, personalized treatment, efficient management of health services, and the democratization of medical knowledge and care. In this comprehensive analysis, we will explore how AI is elevating health outcomes, the mechanisms behind these advancements, its impact on patients and practitioners, challenges faced, and the future outlook of AI-driven healthcare. AI refers to computer systems capable of performing tasks that typically require human intelligence, such as learning, reasoning, pattern recognition, and decision-making. Within healthcare, AI draws upon vast medical datasets—ranging from electronic health records and genetic data to real-time wearable device streams—and applies sophisticated algorithms to uncover patterns, predict outcomes, and recommend optimal interventions. The goal is not to replace clinicians and caregivers but to amplify their abilities, reduce diagnostic errors, and enable personalized, efficient, and timely care. One of the most transformative applications of AI in healthcare is in disease diagnosis, particularly using medical imaging. AI-powered tools can analyze X-rays, CT scans, MRIs, and retinal scans at incredible speeds and with accuracy levels that often match or surpass human experts. Advanced algorithms are trained on millions of medical images, allowing them to detect subtle changes in tissue and anatomical structures that indicate diseases such as: Cancer (breast, lung, skin, and prostate): AI can spot early tumor growths that radiologists might miss, aiding in earlier detection and better patient outcomes. (breast, lung, skin, and prostate): AI can spot early tumor growths that radiologists might miss, aiding in earlier detection and better patient outcomes. Eye diseases : Diabetic retinopathy and age-related macular degeneration can be detected using AI analysis of retinal imagery, helping prevent blindness. : Diabetic retinopathy and age-related macular degeneration can be detected using AI analysis of retinal imagery, helping prevent blindness. Neurological disorders: AI models detect anomalies in brain scans indicating conditions like epilepsy, stroke, and Alzheimer's far more quickly than standard methods. Medical errors are a leading cause of preventable harm. By double-checking, highlighting anomalies, and flagging uncertain cases for further review, AI minimizes oversight. For example, a study showed that AI could detect breast cancer on mammograms with higher sensitivity and specificity than radiologists. No two people are biologically identical. The same disease may progress differently among patients due to genetic, lifestyle, and environmental variations. AI plays a vital role in making precision medicine a reality—treatments are customized based on individual molecular profiles. By analyzing genomic data, AI predicts how a patient will respond to specific drugs, identifies genetic risks, and helps design gene therapies. Continuous glucose monitoring systems empowered by AI adjust diabetes management in real time, analyzing dietary intake, exercise, and blood sugar trends to optimize insulin delivery. Similarly, wearable devices combined with AI alert heart failure patients before their condition worsens, enabling early intervention and reduction in hospitalizations. Conventional drug discovery is costly and time-consuming. AI revolutionizes this process by: Screening millions of compounds for drug candidates at unprecedented speeds. Predicting drug efficacy, optimal dosages, and potential side effects. Personalizing drug combinations for individuals based on genetic makeup and disease behavior. This accelerates the arrival of novel treatments and reduces costs, making medicine more accessible. AI helps predict who is at risk of developing certain conditions (like diabetes, cardiovascular disease, or sepsis) by analyzing medical records, social determinants, and lifestyle data. Early identification allows for proactive interventions—ranging from lifestyle modifications to preemptive medication—which can delay or even prevent disease onset. Hospital readmission within 30 days is costly for both patients and systems. Several health systems use AI algorithms to flag patients at high risk of readmission so care teams can intervene with additional monitoring, support, home visits, or telemedicine follow-ups. AI can detect patterns in public health data, travel patterns, social media signals, and genomic sequencing of pathogens. This helps forecast infectious disease outbreaks (such as influenza, COVID-19, or Ebola), allowing leaders to pre-position resources and enforce public health policies quickly. AI-driven chatbots and voice assistants operate around the clock, answering patient questions, managing appointments, providing medication reminders, and offering first-line triage advice. For individuals with chronic diseases, these tools check on symptoms daily, record vitals, and escalate issues to care teams when necessary. Digital therapeutics use AI-powered mobile apps to deliver behavioral interventions, manage pain, encourage activity, and support mental health. For example, apps can coach users through exercises to relieve chronic pain, offer personalized cognitive behavioral therapy for anxiety and depression, or gamify medication adherence for children. Wearables and home-based sensors collect data on heart rate, blood pressure, oxygen saturation, movement, and even sleep patterns. AI interprets this data, highlighting trends, and alerting caregivers early when intervention is needed, thus enabling proactive care outside the traditional clinic setting. Healthcare systems face immense pressure to improve efficiency while maintaining quality. AI optimizes scheduling, resource allocation, and administrative workflows: Triage : AI-powered systems assist paramedics in determining the severity of ambulance cases and the most appropriate hospital destination, saving time and lives. : AI-powered systems assist paramedics in determining the severity of ambulance cases and the most appropriate hospital destination, saving time and lives. Clinical documentation : Automated transcription and smart note-taking free up doctors from paperwork, allowing more focus on patient care. : Automated transcription and smart note-taking free up doctors from paperwork, allowing more focus on patient care. Billing and claims: AI reviews insurance claims, identifying fraud, reducing errors, and speeding up reimbursement. Clinical trials are expensive and often delayed due to challenges in site selection and patient recruitment. AI helps to: Identify optimal trial sites based on real-world data. Match eligible and diverse participants, ensuring broader and more relevant trial results. Predict and mitigate obstacles—such as withdrawals or protocol violations—by adapting recruitment and retention strategies in real time. By shortening time-to-diagnosis, minimizing preventable admissions, and improving treatment efficacy, AI helps control rising healthcare expenditures. It also contributes to value-based care models by improving outcomes while using fewer resources. AI-powered systems synthesize large volumes of medical literature, guidelines, and individual patient data to provide clinicians with evidence-based recommendations—helping them select the most effective therapies, avoid harmful drug interactions, and keep up with the ever-growing body of medical knowledge. Virtual patients and intelligent simulation platforms powered by AI enhance medical training, allowing clinicians and students to practice complex scenarios and receive tailored feedback. AI also helps identify gaps in knowledge, guiding continuous professional development. A significant proportion of the world's population lacks ready access to quality healthcare, often due to provider shortages, geographic barriers, or cost. AI is helping bridge this gap: Remote diagnostics : AI tools enable health workers in low-resource settings to screen for diseases with smartphone-based imaging and cloud analytics. : AI tools enable health workers in low-resource settings to screen for diseases with smartphone-based imaging and cloud analytics. Automated translation : Multilingual AI models facilitate communication between patients and providers, breaking down language barriers. : Multilingual AI models facilitate communication between patients and providers, breaking down language barriers. Telemedicine platforms: AI-driven services connect patients anywhere with specialists, extending high-level care to underserved areas. The transformative promise of AI comes with substantial challenges: AI depends on sensitive medical data. Ensuring this data is secure, anonymized, and used ethically is paramount. Health organizations must comply with strict privacy regulations and remain vigilant to cyber threats. AI models can perpetuate existing health disparities if trained on unrepresentative data. Biases in algorithms may lead to worse outcomes for minority or marginalized populations. Ongoing efforts focus on transparent data collection, bias detection, and inclusive model development. Clinicians might distrust or resist AI recommendations, especially if the system's reasoning is opaque ('black box' problem). To foster adoption, AI outputs must be explainable and integrated into clinical workflows. AI-enabled devices and software require rigorous regulatory approval to ensure effectiveness and safety. Standards are still evolving, and regulatory bodies worldwide are updating frameworks to keep pace with AI innovation. Google Health's AI model trained on mammograms achieved higher accuracy than radiologists in identifying breast tumors, reducing both false negatives and false positives. This has led to earlier interventions and potentially saved lives. In India, AI-based retinal screening allows technicians to identify diabetic retinopathy in local clinics, referring only urgent cases to distant specialists. This has improved outcomes for thousands who previously lacked access to eye care. AI-powered robots and digital companions provide reminders, monitor mood and safety, and offer social interaction for older adults. These systems, already in use in parts of Europe and Asia, reduce loneliness and delay the need for institutional care. During the pandemic, AI helped accelerate vaccine development, optimize supply chains for personal protective equipment, track outbreaks, and inform public health decision-making by modeling possible scenarios. The journey of AI in healthcare is just beginning. In the coming years, we can expect: Further integration of multi-modal data (genomic, clinical, imaging, behavioral, and social determinants) to enhance predictive power and personalize interventions. Growing democratization of diagnostic and monitoring tools via smartphones and low-cost devices. Real-time adaptive clinical guidelines—algorithms that continuously learn from new data, clinical outcomes, and real-world evidence. Expansion of AI's reach into mental health, voice analysis for neurological and psychiatric disorders, and advanced prosthetics. Closer collaboration between AI developers, clinicians, regulatory bodies, and patients to ensure AI tools are transparent, ethical, and trusted. Artificial intelligence is not a panacea, but it is a catalyst—empowering clinicians, engaging patients, and optimizing the use of resources with the ultimate goal of better health for all. Responsible adoption and ongoing vigilance regarding ethics, equity, and privacy are essential to harness the benefits and minimize risks. As AI continues to evolve, its positive impact on the healthcare ecosystem will become ever more profound, bringing us closer to a future where health is more predictive, personalized, preventive, and accessible TIME BUSINESS NEWS
Business Insider
3 hours ago
- Business Insider
FDA investigating death of child who received Sarepta's Elevidys
The U.S. FDA is investigating the death of an 8-year-old boy who received Elevidys, a Sarepta (SRPT) Therapeutics gene therapy for Duchenne muscular dystrophy. The death occurred on June 7, 2025. The FDA has requested and received voluntary suspension of product distribution as it investigates the safety concerns. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
6 hours ago
- Yahoo
Kennedy to oust care task force, WSJ reports; HHS says no decision yet
By Ahmed Aboulenein and Deena Beasley WASHINGTON (Reuters) -U.S. Health Secretary Robert F. Kennedy Jr. is planning to remove all the members of an advisory panel that determines what cancer screenings and other preventive health measures insurers must cover, the Wall Street Journal reported on Friday, citing people familiar with the matter. A Department of Health and Human Services spokesperson said on Friday that Kennedy had not yet made a decision regarding the 16-member U.S. Preventive Services Task Force. "No final decision has been made on how the USPSTF can better support HHS' mandate to Make America Healthy Again," the HHS spokesperson said. The Journal said Kennedy planned to dismiss all 16 panel members in what would be the latest in a series of far-reaching actions by Kennedy, a long-time vaccine skeptic, to reshape U.S. regulation of vaccines, food and medicine. In June he fired all 17 members of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, a panel of vaccine experts, replacing them with seven handpicked members, including known vaccine skeptics. The USPSTF includes medical experts serving staggered four-year terms on a volunteer basis. Its role in choosing what services will be covered by insurers was established under the 2010 Affordable Care Act, also known as Obamacare. The 40-year-old group, whose recommendations provide guidance to doctors, looks at everything from routine breast cancer screening to drugs to prevent HIV infection. The U.S. Supreme Court in June upheld the constitution of the task force and ruled in favor of its recommendation to cover preventive care. Though made up of an independent group of volunteer experts, members are selected by the health secretary without Senate confirmation and it relies on support from the department's Agency for Healthcare Research and Quality. A group of 104 health organizations, including the American Medical Association and the American Academy of Pediatrics, in early July sent a letter to Congressional health committees, urging them "to protect the integrity" of the task force. The task force has been criticized by some conservatives as too left-leaning.
